Philogen バランスシートの健全性
財務の健全性 基準チェック /66
Philogenの総株主資本は€373.9M 、総負債は€44.0Kで、負債比率は0.01%となります。総資産と総負債はそれぞれ€437.3Mと€63.5Mです。 Philogenの EBIT は€256.9Mで、利息カバレッジ比率-243.1です。現金および短期投資は€379.2Mです。
主要情報
0.012%
負債資本比率
€44.00k
負債
| インタレスト・カバレッジ・レシオ | -243.1x |
| 現金 | €379.22m |
| エクイティ | €373.87m |
| 負債合計 | €63.46m |
| 総資産 | €437.33m |
財務の健全性に関する最新情報
Recent updates
ナラティブ更新 • Jun 26
PHIL: Future Repricing Will Hinge On Lean Margins And Elevated P/E
Analysts have raised their price target on Philogen from €23.00 to about €27.67, citing updated fair value estimates, a slightly higher discount rate, and revised assumptions for revenue trends, profit margins, and future P/E levels. What’s in the News for Philogen No recent Philogen specific news items were identified in the provided sources.ナラティブ更新 • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.
新しいナラティブ • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Apr 06
PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.ナラティブ更新 • Mar 23
PHIL: 2026 Board Schedule Will Support Confidence In Future Repricing Potential
Analysts have kept their price target for Philogen steady at €26.0, indicating only minimal tweaks in the discount rate and forward P/E assumptions, while leaving profit margin expectations unchanged. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company event) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on the first quarter of 2026 (company event) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company event) Board meeting scheduled for November 12, 2026, to approve a press release containing a quarterly report with selected information on the third quarter of 2026 (company event) Valuation Changes Fair Value: kept steady at €26.0 per share, with no change in the central valuation level.ナラティブ更新 • Mar 08
PHIL: 2026 Board Timetable Will Support Confidence In Future Upside
Analysts have left their fair value estimate for Philogen steady at €26.0. They point to only minor tweaks in the discount rate and assumed future P/E that reflect updated risk and earnings assumptions rather than a shift in their overall view. What's in the News Board meeting scheduled for March 27, 2026 to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026 to approve the press release that will contain the quarterly report with selected information on first quarter 2026 performance (company filing) Board meeting planned for September 23, 2026 to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting on November 12, 2026 to approve the press release that will contain the quarterly report with selected information on third quarter 2026 performance (company filing) Valuation Changes Fair Value: Kept steady at €26.0 per share, with no change in the headline estimate.ナラティブ更新 • Feb 21
PHIL: 2026 Board Milestones Will Support Confidence In Future Upside
Analysts have made only a marginal adjustment to their valuation framework for Philogen, keeping the fair value anchor steady at around €26 while fine tuning inputs such as the discount rate, revenue growth assumptions and future P/E to reflect updated risk and earnings expectations. What's in the News Board meeting scheduled for March 27, 2026, to approve the draft financial statements and the 2025 consolidated financial statements (company event calendar).ナラティブ更新 • Feb 06
PHIL: Upcoming Trial Readouts And 2026 Milestones Will Support Upside Potential
Narrative Update on Philogen Analysts now set their price target for Philogen at €26.00, broadly in line with the prior €26 level. This reflects modestly lower discount rate and future P/E assumptions that fine tune their view of the company’s risk and valuation profile.ナラティブ更新 • Jan 23
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have modestly lifted their price target for Philogen to €26.00 per share, reflecting small tweaks to their discount rate and long term P/E assumptions, while keeping fair value otherwise unchanged. What's in the News Philogen provided an update on the FIBROSARC Phase III trial, which tests fibromun plus doxorubicin versus doxorubicin alone as first line treatment for advanced or metastatic soft tissue sarcoma.ナラティブ更新 • Jan 08
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have adjusted their price target for Philogen to €26.00. The change reflects slightly higher perceived risk through a modestly higher discount rate and a broadly unchanged outlook for margins and future P/E assumptions.ナラティブ更新 • Dec 19
PHIL: Future Sarcoma Trial Progress Will Support Upside From Current Levels
Analysts have nudged their price target on Philogen slightly higher to €26.00. This reflects unchanged assumptions on fair value, discount rate, and long term profitability, while acknowledging the resilience of the company’s margin outlook despite subdued growth expectations.ナラティブ更新 • Dec 05
PHIL: Future Trial Milestones And Buyback Activity Will Support Fair Value
Analysts have modestly raised their price target on Philogen to €26.00 per share, reflecting improved expectations for long term profit margins and valuation multiples, despite slightly lower near term revenue growth forecasts. What's in the News Philogen reported updated data from its FIBROSARC Phase III trial of fibromun plus doxorubicin in advanced or metastatic soft tissue sarcoma, with primary endpoint progression free survival and plans to present full results at scientific conferences and in a peer reviewed journal in 2026 (Key Developments).ナラティブ更新 • Nov 20
PHIL: Share Buyback and Stable Financials Will Support Current Fair Value
Narrative Update on Philogen Analysts have maintained their price target for Philogen at €26.00. They cite continued confidence in the company’s outlook despite only minor adjustments to valuation inputs.ナラティブ更新 • Nov 05
PHIL: Share Buyback and Stable Metrics Expected to Sustain Fair Value
Narrative Update: Philogen Price Target Revision Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.ナラティブ更新 • Oct 22
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Analysts have maintained their price target for Philogen at €26.00 per share, citing stable expectations for key financial metrics and future performance. What's in the News Philogen completed the repurchase of 29,448 shares, representing 0.07% of total shares, for €0.66 million under the buyback program announced on May 12, 2025 (Key Developments).ナラティブ更新 • Oct 08
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Analysts have lowered their price target for Philogen from $28.00 to $26.00. This decision is based on revisions in revenue growth projections and a significant reduction in estimated profit margins.分析記事 • Oct 04
Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Despite posting strong earnings, Philogen S.p.A.'s ( BIT:PHIL ) stock didn't move much over the last week. We decided...新しいナラティブ • Aug 20
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.分析記事 • Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Philogen S.p.A. ( BIT:PHIL ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Philogen S.p.A. ( BIT:PHIL ) last week reported its latest yearly results, which makes it a good time for investors to...分析記事 • Feb 24
What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 25.1x Philogen S.p.A. ( BIT:PHIL ) is a stock to avoid...分析記事 • Jun 03
Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...財務状況分析
短期負債: PHILの 短期資産 ( €397.9M ) が 短期負債 ( €51.3M ) を超えています。
長期負債: PHILの短期資産 ( €397.9M ) が 長期負債 ( €12.2M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: PHIL総負債よりも多くの現金を保有しています。
負債の削減: PHILの負債対資本比率は、過去 5 年間で10.3%から0.01%に減少しました。
債務返済能力: PHILの負債は 営業キャッシュフロー によって 十分にカバー されています ( 609009.1% )。
インタレストカバレッジ: PHIL支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。
貸借対照表
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/22 17:43 |
| 終値 | 2026/07/22 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Philogen S.p.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |